Evaluation of Flibanserin: Science and Advocacy at the FDA.
Publication
, Journal Article
Gellad, WF; Flynn, KE; Alexander, GC
Published in: JAMA
September 1, 2015
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
JAMA
DOI
EISSN
1538-3598
Publication Date
September 1, 2015
Volume
314
Issue
9
Start / End Page
869 / 870
Location
United States
Related Subject Headings
- United States Food and Drug Administration
- United States
- Sexual Dysfunctions, Psychological
- National Academies of Science, Engineering, and Medicine, U.S., Health and Medicine Division
- Libido
- Humans
- History, 21st Century
- General & Internal Medicine
- Female
- Drug Approval
Citation
APA
Chicago
ICMJE
MLA
NLM
Gellad, W. F., Flynn, K. E., & Alexander, G. C. (2015). Evaluation of Flibanserin: Science and Advocacy at the FDA. JAMA, 314(9), 869–870. https://doi.org/10.1001/jama.2015.8405
Gellad, Walid F., Kathryn E. Flynn, and G Caleb Alexander. “Evaluation of Flibanserin: Science and Advocacy at the FDA.” JAMA 314, no. 9 (September 1, 2015): 869–70. https://doi.org/10.1001/jama.2015.8405.
Gellad WF, Flynn KE, Alexander GC. Evaluation of Flibanserin: Science and Advocacy at the FDA. JAMA. 2015 Sep 1;314(9):869–70.
Gellad, Walid F., et al. “Evaluation of Flibanserin: Science and Advocacy at the FDA.” JAMA, vol. 314, no. 9, Sept. 2015, pp. 869–70. Pubmed, doi:10.1001/jama.2015.8405.
Gellad WF, Flynn KE, Alexander GC. Evaluation of Flibanserin: Science and Advocacy at the FDA. JAMA. 2015 Sep 1;314(9):869–870.
Published In
JAMA
DOI
EISSN
1538-3598
Publication Date
September 1, 2015
Volume
314
Issue
9
Start / End Page
869 / 870
Location
United States
Related Subject Headings
- United States Food and Drug Administration
- United States
- Sexual Dysfunctions, Psychological
- National Academies of Science, Engineering, and Medicine, U.S., Health and Medicine Division
- Libido
- Humans
- History, 21st Century
- General & Internal Medicine
- Female
- Drug Approval